Projected sales might be 50-100M if FDA granted only the diabetic indication. Only a diabetic indication would be a challenge to ramping up significant sales.
Good idea cleansing. For example cleanse fools who stick to a SP target irrespective of changes in projected market, changes in shares outstanding, changes in FDA timelines, etc etc.
If you think that these Yahoo message boards you are spouting on are important enough that posts can depress share prices, then I bet you also sold rocks as crack back in the day.
Schmucks, hmmm, interesting you'd bring into the conversation SJM, which has far outperformed DVAX last 5-10 years. Kinda makes you wish you'd been an SJM Schmuck all that time versus DVAX.
Heplisav if approved will also sound like one of the commercials on TV, having every possible side effect imaginable including Bell's Palsy.
I doubt the reduced price targets assume full approval. Rather they are targets in advance of the approval process that accomodate the risk of less than full approval. And of course they factor the $300M US-only market. Recall that last time around 2012 the company was touting a market more than double that number with US+Europe. As I recall the number was $700M, although someone here might correct if I'm off.
It seems what we have here is a $14-$15 stock, not too surprising given multiple brokerages a while back reduced price targets substantially to $18-$20. I'd call it fundamentals, looking out 2 years we have at best according to company estimates a $300M per year compound. The "at best" is significant because it assumes a full adult population approval; an approval for less than full adult population approval, certainly a possibility, reduces the $300M number.
At the same time the company is burning through money at a substantial rate, even with no marketing effort as of course the vaccine does not yet have an approval.
I missed that in last presentation. A few here we salivating over the possibility of some statement of efficacy (which was not a Phase I endpoint). So from what you say we should expect total silence from DVAX on the Phase 1?
Thx for the update. Interesting we've heard nothing about the DVAX SD-101 result due "mid-year". A little late ??
Oil, China, Japan, currencies, BREXIT, CAR-T, Italian regulators, Sterling, German Factory Orders, central banks, politicians, bad earnings, Russia, North Korea. atm21money, help me out here, I know you can enumerate many many many more "macro" factors.
Forgot one, huge solar flare that takes out entire US grid, meaning no electricity at DVAX headquarters.
Are you saying his call that Doha OIL Deal would lead DVAX and the entire market down was correct?